Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![OzmosiHealth Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1055982930.png) Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2640 followers
Created: 2025-07-25 13:18:36 UTC

The Phase II trial of KX-826 Tincture XXX% for male adult AGA in China met its primary endpoint.

More Info: $XBI $IBB $XPH $PPH

![](https://pbs.twimg.com/media/GwtL0QfbUAA4OsB.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948734629294604815/c:line.svg)

**Related Topics**
[$pph](/topic/$pph)
[$xph](/topic/$xph)
[$ibb](/topic/$ibb)
[$xbi](/topic/$xbi)
[more info](/topic/more-info)
[china](/topic/china)

[Post Link](https://x.com/OzmosiHealth/status/1948734629294604815)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

OzmosiHealth Avatar Ozmosi @OzmosiHealth on x 2640 followers Created: 2025-07-25 13:18:36 UTC

The Phase II trial of KX-826 Tincture XXX% for male adult AGA in China met its primary endpoint.

More Info: $XBI $IBB $XPH $PPH

XXX engagements

Engagements Line Chart

Related Topics $pph $xph $ibb $xbi more info china

Post Link

post/tweet::1948734629294604815
/post/tweet::1948734629294604815